In this video, Anna Czyz, MD, PhD, Wroclaw Medical University, Wroclaw, Poland, discusses current and future strategies for the management of acute and chronic graft-versus-host disease (GvHD) in patients undergoing allogeneic stem cell transplantation (alloSCT). In recent years, significant progress has been made in the treatment of GvHD due to the introduction of ruxolitinib and extracorporeal photopheresis, and Dr Czyz anticipates further improvements in GvHD management with belumosudil and anti-integrin therapies. This interview took place at the EBMT-EHA 6th European CAR T-cell Meeting in Valencia, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.